» Articles » PMID: 34703415

Non-oestrogenic Modalities to Reverse Urogenital Aging

Overview
Publisher Termedia
Date 2021 Oct 27
PMID 34703415
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Urogenital aging is a common process affecting all women in the post-menopausal period of their life, and it is substantially due to oestrogen deprivation after ovarian function cessation. These changes can lead to a progressive, chronic, and complex association of symptoms identified as the genitourinary syndrome of menopause, which has a significant impact on quality of life. Genitourinary syndrome and urogenital aging do not resolve spontaneously and usually recur when treatment is stopped. Therefore, appropriate long-term management is of paramount importance, and local oestrogen is the most effective treatment to reverse urogenital aging and to improve symptoms of genitourinary syndrome as replacement therapy. In some women, topical oestrogen may be inconvenient, it may not achieve complete response, or it may be contra-indicated. Several non-hormonal therapies have been investigated, but few treatments have been reported as potentially able to reverse the urogenital aging process similarly to exogenous oestrogens. Laser seems the most promising, although further studies to define its safety and efficacy are mandatory. Vitamin D and E, and phytotherapy have returned conflicting results and require further confirmation. Lifestyle modifications, physiotherapy, and electrical stimulation represent inexpensive and applicable treatments that might slow urogenital aging. Among the hormonal non-oestrogenic therapies, the use of vaginal oxytocin and dehydroepiandrosterone have been found to be effective compared to placebo, as well as the use of oral ospemifene, which partially relieves vulvovaginal atrophy.

Citing Articles

Sexual Function in Women Diagnosed with Hereditary Breast and Ovarian Cancer Syndrome.

Ferrari F, Amonti J, Giannini A, Soleymani Majd H, Zizioli V, Tisi G Cancers (Basel). 2024; 16(14).

PMID: 39061239 PMC: 11274699. DOI: 10.3390/cancers16142601.


Laser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis protocol.

Serquiz N, Sarmento A, Almeida N, Nobre M, Medeiros K, Oliveira R BMJ Open. 2023; 13(11):e075841.

PMID: 37949628 PMC: 10649472. DOI: 10.1136/bmjopen-2023-075841.


Efficacy of a Diode Vaginal Laser in the Treatment of the Genitourinary Syndrome of Menopause.

Barba M, Cola A, De Vicari D, Costa C, Castelli A, Volonte S Bioengineering (Basel). 2023; 10(10).

PMID: 37892888 PMC: 10603982. DOI: 10.3390/bioengineering10101158.


Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Current Perspectives on the Role of Laser Therapy.

Cucinella L, Tiranini L, Cassani C, Martella S, Nappi R Int J Womens Health. 2023; 15:1261-1282.

PMID: 37576184 PMC: 10422970. DOI: 10.2147/IJWH.S414509.


Effect of monopolar capacitive resistive radiofrequency in treating stress urinary incontinence: A pilot randomized control trial.

Elhosary E, Hamada H, Ali AlMubali F, Lopez Sanchez G, Ahmed S Front Psychol. 2023; 13:1062363.

PMID: 36687887 PMC: 9851078. DOI: 10.3389/fpsyg.2022.1062363.


References
1.
Portman D, Labrie F, Archer D, Bouchard C, Cusan L, Girard G . Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015; 22(12):1289-95. DOI: 10.1097/GME.0000000000000470. View

2.
Labrie F, Archer D, Koltun W, Vachon A, Young D, Frenette L . Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016; 23(3):243-56. DOI: 10.1097/GME.0000000000000571. View

3.
Mercier J, Morin M, Lemieux M, Reichetzer B, Khalife S, Dumoulin C . Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study. Menopause. 2016; 23(7):816-20. DOI: 10.1097/GME.0000000000000620. View

4.
Bhide A, Khullar V, Swift S, Digesu G . The use of laser in urogynaecology. Int Urogynecol J. 2018; 30(5):683-692. PMC: 6491394. DOI: 10.1007/s00192-018-3844-7. View

5.
Rahn D, Carberry C, Sanses T, Mamik M, Ward R, Meriwether K . Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014; 124(6):1147-1156. PMC: 4855283. DOI: 10.1097/AOG.0000000000000526. View